Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04733963 |
Recruitment Status :
Recruiting
First Posted : February 2, 2021
Last Update Posted : July 26, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer | Drug: Fruquintinib Plus Capecitabine Drug: Bevacizumab Plus Capecitabine | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 112 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Randomized, Controlled Study to Assess the Efficacy and Safety of Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Treatment Following First-line Chemotherapy for Metastatic Colorectal Cancer |
Actual Study Start Date : | March 1, 2021 |
Estimated Primary Completion Date : | January 1, 2023 |
Estimated Study Completion Date : | February 1, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A
Maintenance therapy with Fruquintinib Plus Capecitabine
|
Drug: Fruquintinib Plus Capecitabine
Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal |
Active Comparator: Arm B
Maintenance therapy with Bevacizumab Plus Capecitabine
|
Drug: Bevacizumab Plus Capecitabine
Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal |
- Progression Free Survival [ Time Frame: From Baseline to primary completion date, about 2 years ]Progression-free survival is determined from the date of treatment to PD or death from any cause
- Overall Survival [ Time Frame: From Baseline to primary completion date, about 2 years ]Overall survival is determined from the date of treatment to death from any cause or the last follow-up date
- Adverse Events and Serious Adverse Events [ Time Frame: From Baseline to primary completion date, about 2 years ]Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0.
- QoL [ Time Frame: From Baseline to primary completion date, about 24 months ]Quality of life is assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30. It will be evaluated at Screening, Tumor Assessment Visit and End of Treatment visit.
- Exploratory Endpoint [ Time Frame: From Baseline to primary completion date, about 24 months ]Explore any correlation between clinical outcomes and baseline characteristics, and biomarkers associated with the antitumor activity of fruquintinib based on blood samples
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18-75 years old (including 18 and 75) at the time of signing the informed consent;
- Patients who have been histologically or cytologically confirmed adenocarcinoma of the colon or rectum (stage IV);
- Patients who have achieved disease control (including CR/PR and SD) after 4-6 months of first-line standard chemotherapy (FOLFOX, FOLFIRI, XELOX ± targeted therapy) and are progression free at the start of maintenance therapy;
- At least one measurable metastatic lesion(s) as defined by RECIST version 1.1;
- ECOG performance status of 0-1;
- Body weight ≥40Kg;
- LVEF≥50%;
- Life expectancy≥3 months;
-
Adequate organ and bone marrow functions:
Neutrophils >1.5×109/L, platelets >100×109/L, and hemoglobin >9 g/dL; Total bilirubin <1.5×upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <2.5×ULN (<5×ULN in case of liver metastases); Creatinine clearance (calculated according to Cockcroft and Gault) ≥50 mL/min; Urinary protein / creatinine ratio < 1 (or urine analysis < 1 + or 24-hour urinary protein < 1g / 24 h);
- Able to take oral medication;
- Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration;
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
Exclusion Criteria:
- Pregnant or lactating women;
- Any factors that influence the usage of oral administration;
- Those who have been proved to be allergic to fruquintinib and / or its excipients;
- Blood transfusion was performed within 1 week before randomization;
- Non-controlled hypertension after monotherapy, that is, systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg;
- Intercurrence with one of the following: coronary artery disease, arrhythmia and heart failure;
- Clinically significant electrolyte abnormality;
- Proteinuria ≥ 2+ (1.0g/24hr);
- Previous treatment with VEGFR inhibition;
- Evidence of CNS metastasis;
- Severe intolerance to capecitabine or 5-FU;
- Disability of serious uncontrolled intercurrence infection;
- Uncontrolled hemorrhage in GI;
- Have evidence or a history of bleeding tendency within two months of the enrollment;
- Abdominal fistula or gastrointestinal perforation occurred within 6 months before the first treatment, unless repaired by surgery;
- Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including stroke and transient ischemic attack) , etc.;
- Within 6 months before the first recruitment occurs acute myocardial infarction, acute coronary syndrome or CABG;
- Incomplete healing of skin trauma, surgical site, wound site or severe mucosal ulcer. Bone fracture or wounds that was not cured for a long time;
- APTT and /or PT >1.5×ULN;
- Clinically detectable secondary primary malignancies at the time of enrollment, or had other malignancies in the past 5 years (excluding fully treated basal cell carcinoma of the skin or carcinoma in situ of the cervix);
- Patients who are not suitable for the study judged by the researchers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04733963
Contact: YUAN YING | +86-13858193601 | yuanying1999@zju.edu.cn |
China, Zhejiang | |
the Second Affiliated Hospital of Medical College of Zhejiang University | Recruiting |
Hangzhou, Zhejiang, China, 310000 | |
Contact: Ying Yuan, Ph.D & MD |
Responsible Party: | Ying Yuan, MD, Professor, Second Affiliated Hospital, School of Medicine, Zhejiang University |
ClinicalTrials.gov Identifier: | NCT04733963 |
Other Study ID Numbers: |
FRUCA |
First Posted: | February 2, 2021 Key Record Dates |
Last Update Posted: | July 26, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colorectal Cancer Fruquintinib maintenance |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Bevacizumab |
Capecitabine Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |